CD8A and inflammatory bowel disease: While CD4+ Tregs are well recognized and established, their CD8+ counterparts are still controversial in many regards, including their phenotypic identity and mechanisms of suppression (82); however, the immunosuppressive effects of CD8+ Tregs have been proven in some experimental models such as inflammatory bowel disease and graft-versus-host disease (83, 84).